For NIH staff only, we invite you to join us for a special seminar detailing biomodal’s 6-base multiomic technology for simultaneous genetic and epigenetic biomarker discovery and validation.
Featuring Chennan Li, PhD, Postdoctoral Fellow at the National Cancer Institute, Genitourinary Malignancies Branch, presenting recent work utilizing biomodal’s technology, and Mark Consugar, PhD, Associate Director of Scientific Affairs at biomodal to review technical details, case studies, and data analysis overview.
biomodal’s technology allows you to profile 5‑methylcytosine (5mC) + 5‑hydroxymethylcytosine (5hmC) + whole genome (or targeted DNA panels) simultaneously in a single sample, with as little as 5ng of input DNA. The assay is optimized for FFPE, cell free DNA, liquid biopsy, biofluid samples, and more, and is optimized for use with several NGS technologies. We provide free data analysis software and support in getting up and running and to analyze the data.
AGENDA
- Intro to biomodal at the NIH: Using the 6-base genome to decode health and disease at single-base resolution
Speaker: Mark Consugar, PhD, Associate Director of Scientific Affairs at biomodal. - Embracing the power of liquid biopsy through genome-wide DNA methylation profiling
Speaker: Chennan Li, Postdoctoral Fellow, National Cancer Institute, Genitourinary Malignancies Branch.
Tuesday, June 17, 2025
10:00 AM – 11:00 AM
Virtual attendance link.
